Lushang Freda Pharmaceutical Co.,Ltd. (SHA:600223)
4.880
-0.200 (-3.94%)
Nov 20, 2026, 3:00 PM CST
SHA:600223 Revenue
Lushang Freda Pharmaceutical had revenue of 865.19M CNY in the quarter ending September 30, 2026, with 7.17% growth. This brings the company's total for the last twelve months to 3.83B, up 1.37% year-over-year. In the year 2025, Lushang Freda Pharmaceutical had annual revenue of 3.65B, down -8.33%. That makes Lushang Freda Pharmaceutical the 10,508th largest company in the world by revenue and 1,720th in China.
Revenue (ttm)
3.83B
Revenue Growth
+1.37%
P/S Ratio
1.30
Revenue / Employee
1.09M
Employees
3,514
Market Cap
4.96B
Revenue by Segment
- Pharmaceutical and Chemical Industry 3.08B 84.2%
- Property Management and Other Industries 579.93M 15.8%
Fiscal year ended Dec 31, 2025 See the full SHA:600223 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.65B | -331.68M | -8.33% |
| Dec 31, 2024 | 3.98B | -596.17M | -13.02% |
| Dec 31, 2023 | 4.58B | -8.37B | -64.65% |
| Dec 31, 2022 | 12.95B | 588.17M | 4.76% |
| Dec 31, 2021 | 12.36B | -1.25B | -9.20% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.